Study of an injectable medicine for relapsing multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a new medicine given as a shot under the skin for people with relapsing multiple sclerosis. It aims to see if the medicine is safe and how well it works in reducing MS activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsing-remitting MS or secondary progressive MS with relapses
- You have had recent MS relapses (flare-ups) as described in the study
- You have had an MRI showing changes typical of MS
- You have not had certain prior treatments like stem cell transplants
- You are able to have MRI scans
- Your immune system lab tests are within normal limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
This trial tests whether adding a new medication, RO7268489, to the standard treatment ocrelizumab (Ocrevus) can help people with progressive forms of multiple sclerosis (MS) by slowing disability progression. The trial will evaluate the safety and effectiveness of this combination approach.
This trial tests a new medicine called BCD-281 for people with relapsing-remitting multiple sclerosis (RRMS). It aims to see if the drug can reduce relapses and improve disease control.
This trial tests a new way to give the drug ublituximab (an injection under the skin) to people with relapsing multiple sclerosis. It compares different injection sites and a special auto-injector device to see how the body absorbs the drug and if it's safe.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
Hear when a new Relapsing Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.